BridgeBio Pharma EBITDA Margin 2018-2025 | BBIO

BridgeBio Pharma ebitda margin for the quarter ending March 31, 2025 was -540.63%.

  • BridgeBio Pharma average ebitda margin for 2024 was -239.45%, a 95.41% increase from 2023.
  • BridgeBio Pharma average ebitda margin for 2023 was -5215.45%, a 675.89% decline from 2022.
  • BridgeBio Pharma average ebitda margin for 2022 was -672.19%, a 22.36% increase from 2021.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

BridgeBio Pharma EBITDA Margin 2018-2025 | BBIO

  • BridgeBio Pharma average ebitda margin for 2024 was -239.45%, a 95.41% increase from 2023.
  • BridgeBio Pharma average ebitda margin for 2023 was -5215.45%, a 675.89% decline from 2022.
  • BridgeBio Pharma average ebitda margin for 2022 was -672.19%, a 22.36% increase from 2021.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$15.5B
Dr Reddy's Laboratories (RDY)$11.4B
Bausch Health Cos (BHC)$1.9B
Supernus Pharmaceuticals (SUPN)$1.7B
Amphastar Pharmaceuticals (AMPH)$1.1B
Personalis (PSNL)$282M
Taysha Gene Therapies (TSHA)$254M
Assembly Biosciences (ASMB)$75M
Sol-Gel Technologies (SLGL)$15M
Evoke Pharma (EVOK)$3M
Teligent (TLGT)$0M